Transplantation, Kidney
Conditions
Keywords
erythropoietin, kidney allograft survival, Recombinant Erythropoietin, erythropoietin (Epo)-induced protein 29, human
Brief summary
The study hypothesis is that erythropoietin usage after kidney transplantation, in early phase, can improve the outcome for patients and their graft increasing patient and graft survival.
Interventions
DRUGErythropoietin
sub cutaneous injection, 2000 unit in per injection, 3 times 1 week.
DRUGPlacebo
placebo
Sponsors
Shahid Beheshti University of Medical Sciences
Labbafinejhad Hospital
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
DOUBLE (Subject, Investigator)
Eligibility
Sex/Gender
ALL
Age
18 Years to 55 Years
Healthy volunteers
Yes
Inclusion criteria
* Hb: \>8 and \<10 gr/dl * Age: \>18 and \<55 years * Cholesterol: \<300 mg/dl * Triglyceride: \<400 mg/dl * First Transplantation * Protocol of Immunosuppression: CSA + MMF + Prednisolone * Systolic BP: \<14 * Diastolic BP: \<9
Exclusion criteria
* History of specified cardiac disease * Second Transplantation or more * Hb: \<7gr/dl * The patient needs to infusion of blood * Evidence of local or systemic infection, at the time of EPO injection * Presence of ATN / DGF after transplantation * Presence of emergent hypertension * High risk patients ( Like; PRA\>50%) * Past history of hypersensitivity
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| We will study the well-being of renal function by evaluation of plasma Cr,GFR,PTDA scan & biopsy proven(If it is necessary to prove the rejection)about measuring of patient - graft survival. | May,2008 |
Outcome results
None listed